Botulinum Toxin A Ipsen

The Top 100 Pharmaceutical Companies

The Top 100 Pharmaceutical Companies, determined by total sales in 2011 - see below for 2010 and  2009: They are listed in descending order with the sales in 2011 in $ million; Pfizer ...

To buy or not to buy? Ipsen searches for Inspiration

Ipsen of France has confirmed that its US partner Inspiration Biopharmaceuticals failed to raise third party financing by 30 September 2012. As a result, Ipsen's call option to acquire Inspiration is...

Ipsen signs research accord with Japan's Peptidream

PARIS, April 10 (Reuters) - French pharmaceutical group Ipsen has signed a research partnership with Japan's Peptidream to develop therapeutic peptides for serious diseases in Ipsen's focus areas of n...

IPSEN: Description of the share repurchase program proposed by the Board of Directors to the approval of the Combined Shareholders' Meeting to be held on 31 May 2013

Regulatory News: IPSEN (Paris:IPN): IPSEN Société anonyme with a share capital of €84,118,423 Registered office: 65 quai Georges Gorse 92100 Boulogne-Billancourt France 419 838 529 RCS Nanterre...

Inspiration’s Hemophilia Pact With Ipsen Gets Surprise Revamp

Inspiration Biopharma and hemophilia partner Ipsen have renegotiated their nearly three-year-old deal around two late-stage clinical assets. As part of the new deal, Ipsen has given up its option to b...

Ipsen partners with firm in Japan to develop therapeutic peptides

Japan-based PeptiDream and Ipsen agreed to collaborate in the discovery and development of therapeutic peptides for serious m -More- 

Ipsen Expects Increlex Supply Interruption

PARIS — Ipsen today announced that the supplier of Increlex®'s (mecasermin [rDNA origin] Injection) active ingredient, Lonza, is facing manufacturing issues with Increlex® at its Hopkinton site (M...

Ipsen and Inspiration Biopharma in deal with Baxter for OBI-1

French drugmaker Ipsen (Euronext: IPN) and privately-held US firm Inspiration Biopharmaceuticals have entered into an asset purchase agreement (APA) whereby Baxter International (NYSE: BAX) agrees to...

Ipsen, Inspiration partner to commercialize IB1001 and OBI-1 for hemophilia

Inspiration Biopharmaceuticals Inc. today announced new license, development and commercialization agreements with its strategic partner, Ipsen.

Somatostatin analogs for the treatment of neuroendocrine tumors.

Somatostatin is an important regulator of endocrine and exocrine secretion, affecting the release of many hormones. The effects of somatostatin are mediated through its interaction with one of five so...

New Trends in the Science of Botulinum Toxin-A as Applied in Dystonia.

ABSTRACT New trends and advances in botulinum toxin neuroscience paved the way to the better understanding of the toxin from its behavior at the bench to the clinics. As details of mechanism of action...

{blacktriangledown}Febuxostat for gout.

Around 1.4% of the UK population have gout, the prevalence of which increases with age to around 3% in women and 7% in men aged over 75 years.1-3 Acute gout is intensely painful and can reduce patient...

An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.

A number of experimental models of L-DOPA-induced dyskinesia have been proposed, but these models result in a low to medium rate of dyskinetic animals with mild to severe symptoms. The objective of th...

Novel pharmacological MC4R agonists can efficiently activate mutated-MC4R from obese patients with impaired endogenous agonist response.

Human MC4R (hMC4R) mutations with in vitro functional effects are responsible for 0.5-2.5% of severe obesity. Designing ligands able to counteract this in vitro associated molecular defect is crucial...